Vericel (VCEL) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Vericel (VCEL) overview

Vericel (VCEL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 276m and operating profit of USD 11.0m; the year-end share price was 36.01 USD and market capitalisation was USD 1,823m. Vericel is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vericel's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 355mFY 2025
Share price36.01 USDFY 2025 year end
RevenueUSD 276mFY 2025
Operating profitUSD 11.0mFY 2025
Net earningsUSD 16.5mFY 2025
Market capitalisationUSD 1,823mFY 2025 year end

About Vericel

Vericel develops and markets cell therapy and specialty biologic products for sports medicine and severe burn care. Its products include MACI, an autologous cellularized scaffold used to repair certain knee cartilage defects, and instruments for arthroscopic MACI delivery. It also supplies Epicel, a skin replacement for extensive deep burns, and holds North American rights to NexoBrid, a topical biologic for burn eschar removal.

Generate the Vericel report

Vericel is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Vericel and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Vericel

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.